Blinatumomab + Asciminib
Phase 1/2Recruiting 1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Philadelphia Chromosome-Positive
Conditions
Philadelphia Chromosome-Positive, Acute Lymphoblastic Leukemia
Trial Timeline
Aug 5, 2024 → May 1, 2029
NCT ID
NCT06308588About Blinatumomab + Asciminib
Blinatumomab + Asciminib is a phase 1/2 stage product being developed by Novartis for Philadelphia Chromosome-Positive. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06308588. Target conditions include Philadelphia Chromosome-Positive, Acute Lymphoblastic Leukemia.
What happened to similar drugs?
2 of 8 similar drugs in Philadelphia Chromosome-Positive were approved
Approved (2) Terminated (1) Active (5)
Hype Score Breakdown
Clinical
9
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06308588 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Philadelphia Chromosome-Positive
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Imatinib Mesylate | Novartis | Phase 2 | 35 |
| Nilotinib | Novartis | Phase 3 | 32 |
| Nilotinib | Novartis | Phase 3 | 40 |
| STI571 400 mg + STI571 600 mg | Novartis | Phase 2 | 35 |
| Induction Phase + Re-Induction Phase + Post-Remission + Maintenance | Novartis | Phase 2 | 42 |
| nilotinib | Novartis | Phase 2 | 35 |
| Asciminib + Nilotinib | Novartis | Phase 3 | 44 |
| imatinib mesylate | Novartis | Phase 2 | 35 |
| Asciminib | Novartis | Phase 1 | 36 |
| Asciminib Pediatric formulation group + Asciminib Adult formulation group | Novartis | Phase 1/2 | 39 |
| Nilotinib + LDE225 | Novartis | Phase 1 | 29 |
| Nilotinib | Novartis | Approved | 43 |
| Imatinib + Nilotinib + Bosutinib + Dasatinib + Asciminib | Novartis | Phase 3 | 44 |
| Asciminib | Novartis | Approved | 47 |
| Blinatumomab | Amgen | Phase 2 | 35 |
| Treatment with blinatumomab given subcutaneously. | Amgen | Phase 2 | 42 |
| Blinatumomab + Blinatumomab + HyperCVAD | Amgen | Phase 3 | 47 |
| Blinatumomab + Low-intensity chemotherapy regimen + SOC chemotherapy regimen | Amgen | Phase 3 | 47 |
| Bosutinib | Pfizer | Phase 1/2 | 36 |
| Bosutinib + Bosutinib | Pfizer | Phase 1 | 29 |